KR20200035073A - 국소 피부 저형성 질환의 치료 - Google Patents

국소 피부 저형성 질환의 치료 Download PDF

Info

Publication number
KR20200035073A
KR20200035073A KR1020207005199A KR20207005199A KR20200035073A KR 20200035073 A KR20200035073 A KR 20200035073A KR 1020207005199 A KR1020207005199 A KR 1020207005199A KR 20207005199 A KR20207005199 A KR 20207005199A KR 20200035073 A KR20200035073 A KR 20200035073A
Authority
KR
South Korea
Prior art keywords
mrna
lys
gly
leu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207005199A
Other languages
English (en)
Korean (ko)
Inventor
마르쿠스 만들러
프란크 마트너
발터 슈미트
아힘 슈네베르거
Original Assignee
아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게 filed Critical 아카니스 바이오테크 에프운트에 게엠베하 운트 콤파니 카게
Publication of KR20200035073A publication Critical patent/KR20200035073A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207005199A 2017-07-31 2018-07-31 국소 피부 저형성 질환의 치료 Withdrawn KR20200035073A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183990.5A EP3437650A1 (en) 2017-07-31 2017-07-31 Treatment of local skin hypotrophy conditions
EP17183990.5 2017-07-31
PCT/EP2018/070712 WO2019025431A1 (en) 2017-07-31 2018-07-31 TREATMENT OF LOCAL SKIN HYPOTROPHIC CONDITIONS

Publications (1)

Publication Number Publication Date
KR20200035073A true KR20200035073A (ko) 2020-04-01

Family

ID=59506101

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005199A Withdrawn KR20200035073A (ko) 2017-07-31 2018-07-31 국소 피부 저형성 질환의 치료

Country Status (8)

Country Link
US (1) US20200369738A1 (https=)
EP (2) EP3437650A1 (https=)
JP (2) JP2020529208A (https=)
KR (1) KR20200035073A (https=)
CN (1) CN111050785A (https=)
AU (1) AU2018311128A1 (https=)
CA (1) CA3070880A1 (https=)
WO (1) WO2019025431A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432810B1 (ko) * 2021-10-29 2022-08-16 주식회사 엣지케어 약물전달 시스템 및 약물전달 시스템의 동작방법

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012683A (es) * 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
US20220015986A1 (en) * 2020-07-16 2022-01-20 Hillary Hayman Three-step process for mimicking plastic surgery results
CN114717230B (zh) * 2021-01-05 2024-09-03 麦塞拿治疗(香港)有限公司 成纤维细胞生长因子mRNA的无细胞和无载体体外RNA转录方法和核酸分子
WO2023012722A1 (en) * 2021-08-06 2023-02-09 Leadermed Champion Limited miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF
WO2024151673A2 (en) * 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
CN120137909A (zh) * 2025-03-12 2025-06-13 广州酷奇圈科研与推广应用有限公司 重组外泌体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1168997B1 (en) 1999-04-02 2013-04-24 KCI Licensing, Inc. Vacuum assisted closure system with provision for introduction of agent
US7202226B2 (en) * 2000-10-23 2007-04-10 Detroit R & D Augmentation of wound healing by elF-4E mRNA and EGF mRNA
KR20060123256A (ko) * 2003-11-11 2006-12-01 가부시키가이샤 시세이도 모발의 태모화 방법 및 조성물
US7816140B2 (en) 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
RU2008128451A (ru) * 2005-12-14 2010-01-20 Огенодженесис, Инк. (US) Композиция для лечения и ухода за кожей, способ ее получения, способ ее использования
US20100143289A1 (en) 2006-12-19 2010-06-10 Michael Cohen Umbilical cord stem cell secreted product derived topical compositions and methods of use thereof
WO2009030464A2 (de) 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
WO2009119073A1 (ja) * 2008-03-28 2009-10-01 北海道公立大学法人札幌医科大学 皮膚の老化や瘢痕の治療剤
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PT2670411T (pt) 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
US8759287B2 (en) 2011-04-12 2014-06-24 M-3 Biologics, Llc Methods of decreasing incisional hernia formation and acute wound failure in obese patients by administering basic fibroblast growth factor
WO2013002331A1 (ja) * 2011-06-28 2013-01-03 株式会社バイオセレンタック 皮膚治療用微細針集積型製剤
US9439940B2 (en) 2011-07-19 2016-09-13 Neville Pharmaceutical, Inc. Topical transdermal method for delivering nutrients through the skin for expeditied wound healing and skin rejuvenation
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
EP4331620A3 (en) 2012-12-07 2024-12-04 Translate Bio, Inc. Lipidic nanoparticles for mrna delivery
RS57739B1 (sr) 2013-03-14 2018-12-31 Translate Bio Inc Kompozicije cftr irnk i postupci i upotrebe u vezi sa njima
EP3099801B1 (en) * 2014-01-31 2020-03-18 Factor Bioscience Inc. Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
WO2016100820A2 (en) 2014-12-19 2016-06-23 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102432810B1 (ko) * 2021-10-29 2022-08-16 주식회사 엣지케어 약물전달 시스템 및 약물전달 시스템의 동작방법
WO2023075105A1 (ko) * 2021-10-29 2023-05-04 주식회사 엣지케어 약물전달 시스템 및 약물전달 시스템의 동작방법

Also Published As

Publication number Publication date
EP3661540A1 (en) 2020-06-10
JP2023145532A (ja) 2023-10-11
CA3070880A1 (en) 2019-02-07
JP2020529208A (ja) 2020-10-08
CN111050785A (zh) 2020-04-21
WO2019025431A1 (en) 2019-02-07
EP3437650A1 (en) 2019-02-06
US20200369738A1 (en) 2020-11-26
AU2018311128A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
KR20200035073A (ko) 국소 피부 저형성 질환의 치료
Zhang et al. In situ-formed adhesive hyaluronic acid hydrogel with prolonged amnion-derived conditioned medium release for diabetic wound repair
Tkalčević et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression
Branski et al. Gene therapy in wound healing: present status and future directions
Carleton et al. Methacrylic acid-based hydrogels enhance skeletal muscle regeneration after volumetric muscle loss in mice
KR102040710B1 (ko) 피부 흉터형성을 치료하기 위한 조성물 및 방법
Shi et al. CARP, a cardiac ankyrin repeat protein, is up-regulated during wound healing and induces angiogenesis in experimental granulation tissue
JP2008530003A (ja) 創傷治癒を向上させるための、および線維症予防のためのミオスタチン（ｇｄｆ−８）アンタゴニストの使用
KR102527367B1 (ko) 탄력섬유의 생체 내 합성
KR20100027091A (ko) 상처 치유를 위한 개선 방법 및 조성물
Farwick et al. Fifty-kDa hyaluronic acid upregulates some epidermal genes without changing TNF-α expression in reconstituted epidermis
US12343420B2 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
Sahl Jr et al. Cutaneous scars: part I.
JP2015057431A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
KR20190133216A (ko) 비흑색종 피부암(nmsc)의 예방 및 치료
Zhao et al. Delayed wound healing in the elderly and a new therapeutic target: CD271
US12006501B2 (en) Composition of drug targets and method of using thereof
KR20080017411A (ko) 상처 치유용 조성물 및 그의 용도
Shirakata et al. So-called biological dressing effects of cultured epidermal sheets are mediated by the production of EGF family, TGF-β and VEGF
EP2968462B1 (en) Methods for promoting wound healing and hair growth
EP1671655A1 (en) Gene therapy for skin diseases using needle free syringe
US20230220026A1 (en) Nucleic acid carrier for producing the single-chain vegf fusion protein with high physiological stability and dimeric efficiency, preparation method thereof, and use thereof
Kolostova et al. Wound healing gene therapy: cartilage regeneration induced by vascular endothelial growth factor plasmid
Xiao et al. Hyaluronic Acid Hydrogel‐Mediated Delivery of MSC‐Derived Exo‐FGF21 Promotes Spinal Cord Injury Repair via STAT3/SOCS3 Signaling
da Costa Manso et al. Regenerative Therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200221

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210729

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20231207

WITB Written withdrawal of application